Integrated Biopharma Inc's ROA from the fourth quarter of 2026 to the fourth quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Integrated Biopharma Inc's ROA in the fourth quarter of 2026?
Integrated Biopharma Inc recorded a cumulative net loss of $-3 million during 12 months ending in the fourth quarter of 2026, resulting in a negative return on assets (ROA) of -10%.

However, within the Healthcare sector 301 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2026 from 3051 to 3055.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) IV. Quarter	(Mar 31 2026) III. Quarter	(Dec 31 2025) II. Quarter	(Sep 30 2025) I. Quarter	(Jun 30 2025) IV. Quarter
Y / Y Total Assets Change	8.79 %	4.95 %	-4.98 %	-2.46 %	-1.33 %
Y / Y Net Income Change	-	-	-	-52.51 %	-
Net Income (TTM) in million	-3	-2	0	1	1
Return On Assets (TTM)	-10 %	-5.98 %	-0.75 %	2.43 %	2.9 %
INBP's Total Ranking	# 3055	# 3051	# 1683	# 1545	# 1233
Total Assets (TTM) in million	37	27	25	26	34
Seq. Total Assets Change	36.96 %	7.1 %	-2.5 %	-23.93 %	32.12 %
Seq. Net Income Change	-	-	-	-	-

INBP's 5 Years Annual ROA >> Back to INBP Management Effectiveness >> Compare INBP ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 107
Sector	# 302
Overall	# 3205

Return On Assets Statistics
High	Average	Low
31.59 %	7.14 %	-16.77 %
(Jun 30 2021)		(Sep 30 2012)

Financial Statements
Integrated Biopharma Inc's Assets	$ 37 million	INBP's Balance sheet
Integrated Biopharma Inc's Income	$ -1 million	Quarterly INBP's Income Statement
INBP's Income by Division		See INBP's Income by Division

Annual Return On Assets	(Jun 30 2026) FY 2026	(Jun 30 2025) FY 2025	(Jun 30 2024) FY 2024	(Jun 30 2023) FY 2023	(Jun 30 2022) FY 2022
Y / Y Total Assets Change	46.68 %	-4.98 %	8.82 %	-4.63 %	1.79 %
Total Assets in million	37	25	26	24	25
Y / Y Net Income Change	-	621.43 %	-	-	-52.1 %
Net Income in million	-3	1	0	0	4
Annual Return On Assets	-7.78 %	3.24 %	0.43 %	-0.14 %	15.2 %

INBP's 5 Years Annual ROA >> Back to INBP Management Effectiveness >> Compare INBP ROA to its Competitors

More Return On Assets Ratios
INBP's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
INBP's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for INBP's Competitors
Subscribers only: Roa for Integrated Biopharma Inc's Suppliers
Subscribers only: Return On Assets for INBP's Customers

You may also want to know
INBP's Roi	INBP's Inventory Turnover Ratio	INBP's Growth Rates	INBP's Dividend Comparisons
	INBP's Profitability Ratios	INBP's Asset Turnover Ratio	INBP's Dividend Growth
INBP's Roe	INBP's Valuation Ratios	INBP's Financial Strength Ratios	INBP's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-27T08:12:16+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.